The burden of cancer in Mexico, 1990-2013

Gómez–Dantés, Héctor; Lamadrid‐Figueroa, Héctor; Cahuana-Hurtado, Lucero; Silverman-Retana, Omar; Montero, Pablo H.; González-Robledo, María Cecilia; Fitzmaurice, Christina; Pain, Amanda; Allen, Christine A.; Dicker, Daniel; Hamavid, Hannah; López, Alan D.; Murray, Christopher J L; Naghavi, Mohsen; Lozano, Rafael

doi:10.21149/spm.v58i2.7780

Cited by 66 publications

(72 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Investigaciones anteriores realizadas en una población mexicana informaron una tasa de incidencia de 1.4 por 100,000 personas-año 6 , lo que contrasta con nuestros resultados. Sin embargo, de acuerdo con nuestros hallazgos, otro estudio encontró una tasa de incidencia de 1.8 por 100,000 personas-año en México 19 . Esta discrepancia puede deberse a razones metodológicas, ya que el segundo estudio mencionado y el nuestro utilizaron un conjunto más completo de fuentes de datos, mientras que el primero utilizó un registro de cáncer único.…”

Section: Discussionunclassified

“…Este hallazgo es consistente con las investigaciones previas para LH en México, que se estima en 0.48 6 . Sin embargo, otros investigadores reportaron una tasa de mortalidad específica de 0.7 para el periodo 1990-2013 19 . Los autores también encontraron un decremento en las tasas de mortalidad durante ese periodo, lo cual podría explicar las tasas de mortalidad más bajas presentadas aquí.…”

Section: Discussionunclassified

“…Para comprender el estado clínico y el tratamiento de los pacientes con LH, entrevistamos a especialistas médicos siguiendo la metodología Delphi 19 . Diseñamos un instrumento para recopilar datos a partir de la revisión de la literatura médica sobre LH disponible hasta 2018.…”

Section: Metodologíaunclassified

See 2 more Smart Citations

Linfoma de Hodgkin: carga de la enfermedad en México. Construcción de una medida proxy con datos administrativos del Sistema Nacional de Salud

Rivas-Vera¹,

Ramírez-Ibarguen²,

Figueroa-Acosta³

2019

GAMO

View full text Add to dashboard Cite

ArtíCuLo origiNAL resumen introducción: Las nuevas terapias han aumentado la supervivencia del linfoma de Hodgkin (LH) en los países desarrollados, no en el resto. En México faltan sistemas de vigilancia para el LH. Métodos: Desarrollamos un proxy para la carga del LH en México utilizando datos administrativos de: prevalencia, incidencia, hospitalizaciones y mortalidad. La población consistió en individuos que asistieron a cualquier institución mexicana durante el 2016 y fueron registrados con el código C81 de la Clasificación internacional de enfermedades (CIE)-10. El denominador de las tasas fue la población específica por edad del censo. Se realizaron entrevistas sobre tratamiento del LH con especialistas. resultados: Durante 2016, respecto al LH, se registraron 2,278 casos nuevos, 3,241 hospitalizaciones y 535 muertes. Las tasas de incidencia de LH fueron un 32% superiores en los hombres. Los adultos de ≥ 60 años tuvieron las tasas de incidencia más altas de LH, seguidos de los adultos entre 20 y 24 años. Las estrategias de tratamiento del LH fueron diferentes entre el sector público y el privado. Conclusión: El cuadro epidemiológico del LH en México muestra un patrón de incidencia similar al de los países desarrollados. Nuestro proxy de la carga del LH servirá para planificar y monitorear futuras estrategias contra el cáncer.Palabras clave: Linfoma de Hodgkin. México. Carga. Epidemiología. Tasa de incidencia. Abstract introduction: While new therapies have increased survival for Hodgkin lymphoma (HL) in developed nations, the developing world still carries with most of the burden of this disease. Nevertheless, surveillance mechanisms for HL are lacking in Mexico.Methods: We developed a proxy for the burden of HL in Mexico using administrative data considering its prevalence, incidence, hospitalizations and mortality. The population consisted in individuals with International classification of diseases-10 code C81 attended in all Mexican institutions during 2016. The denominator of the rates was the age-specific population from census data. Structured interviews about treatment of HL were conducted with clinicians. results: During 2016, 2,278 cases of HL were diagnosed; 3,241 patients were hospitalized and 535 died. The incidence rates of HL were 32% higher in males versus females. Adults aged 60 years or older had the highest incidence rates of HL, followed by adults between 20 and 24 years old. The strategies to treat HL were different between physicians working for the public and the private sector.1665-9201/Conclusion: The epidemiologic picture of HL in Mexico exhibits a pattern similar to that of developed countries. Our surrogate for the burden of HL will serve to plan and monitor future national cancer strategies.

show abstract

Section: Discussionunclassified

See 1 more Smart Citation

Linfoma de Hodgkin: carga de la enfermedad en México. Construcción de una medida proxy con datos administrativos del Sistema Nacional de Salud

Rivas-Vera¹,

Ramírez-Ibarguen²,

Figueroa-Acosta³

2019

GAMO

View full text Add to dashboard Cite

show abstract

“…Mexico achieves a lot to decrease morbidity and mortality associated with undernourishment, transmittable infectious diseases such as diarrheal diseases and sanitation, especially among the pediatric population [53][54][55] . Nevertheless, the fifth principal burden of chronic NCDs became the major basis of public health apprehension [54][55][56] . Additionally, diabetes mellitus appears as the sole principal cause of disability-adjusted life years and expected to deteriorate in the upcoming day 57,58 .…”

Section: Amexicomentioning

confidence: 99%

Prospects and Challenges of Precision Medicine in Lower- and Middle-Income Countries: A Brief Overview

Haque

Islam

Sartelli

et al. 2019

Bangladesh J Med Sci

View full text Add to dashboard Cite

The trend of NCDs in most LMIC countries is slowly but gradually follows that of in the developed countries. There are four significant diseases reported by WHO, which are equally common, such as CVDs, diabetes, cancer, and chronic respiratory disease that causes widespread early death & morbidity. Indeed, it incurs an overwhelming financial burden to most countries in the world. The rise of drug-resistant microbes is another major problem. To overcome this issue, precision medicine (PM) comes into play whereby individual variability in genes, environment, lifestyle, and nutrition of each person is considered for disease treatment & prevention. PM provides a personalized approach, the right treatment to the right people at the right time. Many wealthy countries in the West have started adopting PM though the initial cost is high, ultimately, in the long run, will reduce the healthcare cost by getting rid of the ineffective treatment strategies. However, the PM in LMICs is still at an early stage due to issues such as lack of populationspecific data, competency, expertise, and poor financial support. Bangladesh Journal of Medical Science Vol.19(1) 2020 p.32-47

show abstract

“…(4) In Mexico, as in other middle-income countries, CRC incidence and mortality are on the rise, possibly due to the combined effect of changing lifestyles and the improvement of healthcare infrastructure to facilitate diagnosis. (8) Unfortunately, a large proportion of cases are diagnosed at advanced stages, resulting in poor outcomes. (9) Even though the Mexico's National Clinical Practice Guidelines recommend annual gFOBT for average-risk individuals, efforts to formally implement CRC screening programs in Mexico are nascent.…”

Section: Introductionmentioning

confidence: 99%

Barriers and facilitators for colorectal cancer screening in a low-income urban community in Mexico City

Unger‐Saldaña¹,

Saldaña-Téllez²,

Potter

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) incidence and mortality are increasing in many middle- and lower-income countries, possibly due to a combination of changing lifestyles and improved healthcare infrastructure that facilitates diagnosis. Unfortunately, a large proportion of cases may be diagnosed at advanced stages, resulting in poor outcomes. Decreasing trends in higher income countries are likely due to improved early detection combined with best practices in CRC treatment and management. More data on implementation of better quality CRC screening programs are needed for contexts where incidence is increasing. Therefore, we sought to identify potential barriers and facilitators for future implementation of fecal immunochemical test (FIT)-based CRC screening in a public healthcare system in a middle-income country with increasing CRC incidence and mortality. Methods. Qualitative study including semi-structured individual and focus group interviews with different stakeholders of colorectal cancer screening: 30 average-risk lay people, 13 health care personnel from a local public clinic, and 7 endoscopy unit personnel from a cancer referral hospital. All interviews were transcribed verbatim for analysis. Data was analyzed using the constant comparison method, under the theoretical perspectives of the Social Ecological Model (SEM), the PRECEDE-PROCEED Model, and the Health Belief Model. Results. We found multiple barriers and facilitators for implementation of a FIT-based CRC screening program at different levels of the SEM. The main barriers in each of the SEM levels, were: 1) at the social context level: poverty, health literacy and lay beliefs related to gender, cancer, allopathic medicine, and religion; 2) at the health services organization level: the lack of CRC knowledge among health care personnel and the community perception of poor quality of health care; 3) at the individual level: a lack of CRC awareness and therefore lack of risk perception, together with fear of participating in screening activities and finding out about a serious disease. The main facilitators perceived by the participants were CRC screening information and the free provision of screening tests.Conclusions. This study’s findings suggest the need for a multi-level CRC screening program that includes complementary strategies aimed at reducing perceived barriers and enhancing facilitators, starting with: 1) free provision of screening tests, 2) education of primary health care personnel, and 3) promotion of non fear-based CRC screening awareness among the target population, taking into account their lay beliefs.

show abstract

The burden of cancer in Mexico, 1990-2013

Cited by 66 publications

References 44 publications

Linfoma de Hodgkin: carga de la enfermedad en México. Construcción de una medida proxy con datos administrativos del Sistema Nacional de Salud

Linfoma de Hodgkin: carga de la enfermedad en México. Construcción de una medida proxy con datos administrativos del Sistema Nacional de Salud

Prospects and Challenges of Precision Medicine in Lower- and Middle-Income Countries: A Brief Overview

Barriers and facilitators for colorectal cancer screening in a low-income urban community in Mexico City

Contact Info

Product

Resources

About